Latest News
- Wall Street Initiation on Synergy Pharma Gets The Stock Moving
By Jake King · Mon, Jun 17
Synergy Pharmaceuticals (SGYP) is well-funded, with over $100 million in cash after its last capital raise, and the weakening biotech tape of late enables · more » - Good News for this Small-Cap Biotech: Eli Lilly Wants to Develop its Diabetes Drug
By Jake King · Mon, Jun 17
Large-cap drug company Eli-Lilly (LLY) must have liked what it saw in April when Transition Therapeutics (TTHI) reported its Phase Ib proof-of-concept · more » - Liquidity and a Discounted Deal Aren’t Ideal for this Chancy Biotech Equity
By Jake King · Mon, Jun 17
Intercept Pharmaceuticals (ICPT) on Monday morning announced the sale of 1.73 million shares of common stock (2 million with underwriter’s · more » - Questcor: The Bear Theses Continue to Unravel
By Jake King · Wed, Jun 12
Questcor Pharmaceuticals’ (QCOR) purchase of Synacthen on Tuesday, a synthetic melanocortin receptor agonist, from Novartis (NVS) is good news for the · more » - Infinity Pharma’s Safety Concerns: For Patient Investors, a Buying Opportunity
By Ivan Deryugin · Mon, Jun 10
As one of the premier medical conferences globally, the annual meeting of the American Society for Clinical Oncology has the potential to create or · more » - The Market Likes Endo Health’s New Strategy: You Should Too
By Jake King · Thu, Jun 6
Endo Health Solutions’ (ENDP) new CEO is executing on his strategy, as expected, and most of the Street likes what it sees. Endo announced on Wednesday · more » - Zogenix Is Having a Hard Time with its Capital Needs
By Jake King · Wed, Jun 5
Zogenix (ZGNX) in a press release Wednesday morning said that it is undertaking cost-control initiatives in order to achieve key business milestones in · more » - Knee-Jerk Market Reaction to BioMarin Data Undue
By Jake King · Tue, Jun 4
BioMarin (BMRN) took a beating on Monday as more mature data at the American Society for Clinical Oncology meeting for its Phase I PARP inhibitor, · more » - Solid Showing At WCN Conference For Keryx: Catalysts Still To Come
By Jake King · Mon, Jun 3
Keryx Biopharmaceuticals (KERX) presented additional details from its pivotal Phase III study for Zerenex Monday at the World Congress of Nephrology (WVN) · more » - For the Long-Term Investor, Sarepta’s Immediate Events Matter Little
By Jake King · Fri, May 31
PropThink’s readers will be aware of our bullish outlook on Sarepta Therapeutics (SRPT), and Thursdays commentary that a NDA filing may still be months · more » - Neuralstem Sees Breakthrough In Spinal Cord Injury
By Jason Napodano, CFA · Thu, May 30
Earlier in the week, Neuralstem, Inc (CUR) announced the publication of preclinical data in the journal of Stem Cell Research Therapy demonstrating that · more » - Cubist Commands the Courtroom: Investors Can Now Focus On Long-Term Story
By Jake King · Tue, May 21
Things are looking up for Cubist Pharmaceuticals (CBST). As we speculated last week, a key piece of Cubist’s ongoing litigation with Hospira has gone in · more » - Revisiting Synergy Ahead of An Event-Driven Week: Plecanatide Data is Forthcoming
By Jake King · Fri, May 17
This Tuesday, Synergy Pharmaceuticals (SGYP) will release the full data set from its recently completed trial for lead candidate plecanatide at the annual · more » - An FDA Meeting Becomes New Focus for Titan Pharma
By Jason Napodano, CFA · Fri, May 17
On May 16, 2013, Titan Pharmaceuticals (TTNP) reported financial results and provided a brief update on the recent complete response letter (CRL) issued · more » - Ahead of Incremental Catalysts, Immunomedics’ Options are Compellingly Priced
By Ivan Deryugin · Wed, May 15
Since our original March 1 report highlighting Immunomedics (IMMU) as an inexpensive biotech with a novel platform and deep pipeline, shares have risen · more » - MAKO Surgical: Burden of Proof Still on Management
By Jake King · Thu, May 9
MAKO Surgical’s (MAKO) first quarter results did little to inspire our confidence in this battered and bruised story, but for those that truly believe · more » - Previewing MAKO Surgical’s First Quarter: A Pivotal Earnings Release
By Ivan Deryugin · Mon, May 6
Within biotechnology and the broader healthcare sector, investor sentiment often reaches extremes. A company might be heralded as a revolution in medicine · more » - The ODAC Postmortem: Lessons Learned Part 2, Delcath Systems
By Aafia Chaudhry, MD · Mon, May 6
In part 2 of the ODAC postmortem (see Part 1 on Aveo Oncology [AVEO] here), I will share my thoughts on the outcome of the afternoon session which · more » - Picking Up What’s Left of Aveo
By Jake King · Fri, May 3
Although shares of Aveo Oncology (AVEO) were crushed this week by a negative vote from the FDA’s Oncologic Drugs Advisory Committee regarding tizozanib · more » - The ODAC Postmortem: Lessons Learned Part 1, AVEO
By Aafia Chaudhry, MD · Fri, May 3
Yesterday was a dark day for those holding Aveo Oncology (AVEO) or Delcath Systems (DCTH) through the FDA’s Oncologic Drugs Advisory Committee meeting. · more » - Despite Poor Quarter, ViroPharma’s Commercial and Pipeline Progress Continue
By Ivan Deryugin · Fri, May 3
Shares of ViroPharma fell 6.9% on May 1 with the release of mixed first quarter results, also amidst a weak day for the biotechnology sector driven · more » - Durect: Pfizer Hints At Progress With Remoxy
By Jason Napodano, CFA · Fri, May 3
Investors are well aware, the single biggest catalyst for shares of DURECT Corp. (DRRX) remains the filing of the Remoxy NDA by Pfizer (PFE). As such, · more » - Watching Zalicus Like A Hawk
By Jason Napodano, CFA · Thu, May 2
Zalicus (ZLCS) is starting to look very interesting at this level. Traders are no doubt waiting for the big phase 2 data on potential blockbuster drug · more » - Undue Pressure on Trius Creates an Entrance Point
By Jake King · Thu, May 2
Shares of Trius Therapeutics (TSRX) took a 7% dive on Wednesday, creating an entrance opportunity for those not yet involved, as the unsubstantiated · more » - FDA Rejection Of Probuphine Hits Titan Hard
By Jason Napodano, CFA · Wed, May 1
On April 30, 2013, Titan Pharmaceuticals (TTNP) announced that the U.S. FDA had issued a complete response letter (CRL) to its new drug application · more » - Weak Quarter at Auxilium Overshadows Execution on Long-Term Strategy
By Ivan Deryugin · Wed, May 1
Shares of Auxilium Pharmaceuticals (AUXL) fell nearly 13% on April 29 after the company released weak Q1 earnings, and are down around 12% since our · more » - Transition Therapeutics Still Undervalued: Good Trial Outcome Shifts Focus To Lilly Decision
By Jake King · Tue, Apr 30
Transition Therapeutics (TTHI) announced on Tuesday morning that its investigational GLP-1/glucagon agonist, TT-401, generated positive results in its · more » - Binary Events Abound in Biotech
By Editorial Staff · Mon, Apr 29
As most biotech enthusiasts will be well-aware of, biotech is rife with binary events this week, many of which fall on Tuesday April 30. While PropThink · more » - Raised Guidance and Resolved Manufacturing Issues Support Alexion Shares
By Ivan Deryugin · Mon, Apr 29
Since our last report on Alexion Pharmaceuticals (ALXN) on April 5, shares have remained flat as continued concerns about the company’s manufacturing · more » - Illumina’s Solid Quarter Highlights Macroeconomic Resilience & Market Opportunity
By Ivan Deryugin · Thu, Apr 25
On April 22, after the close of trading, Illumina (ILMN) released its Q1 2013 earnings, delivering another solid quarter in the face of perceived · more »